These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 18720308)

  • 41. Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients.
    Salluh JI; Soares M; De Meis E
    Clinics (Sao Paulo); 2009; 64(2):79-82. PubMed ID: 19219311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sudden sensorineural hearing loss and antiphospholipid syndrome.
    Wiles NM; Hunt BJ; Callanan V; Chevretton EB
    Haematologica; 2006 Dec; 91(12 Suppl):ECR46. PubMed ID: 17194652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antiphospholipid syndrome and venous thromboembolism: the role of congenital thrombophilia].
    Poli D; Gensini GF
    Ann Ital Med Int; 2005; 20(4):218-23. PubMed ID: 16610253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Infant perinatal thrombosis and antiphospholipid antibodies: a review.
    Boffa MC; Lachassinne E
    Lupus; 2007; 16(8):634-41. PubMed ID: 17711900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons".
    Ceccarelli F; Chighizola C; Finazzi G; Meroni PL; Valesini G
    Autoimmun Rev; 2012 Jun; 11(8):568-71. PubMed ID: 22036825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism.
    de Laat B; Mertens K; de Groot PG
    Nat Clin Pract Rheumatol; 2008 Apr; 4(4):192-9. PubMed ID: 18285765
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical profiles and risk assessment in patients with antiphospholipid antibodies.
    Kato M; Hisada R; Atsumi T
    Expert Rev Clin Immunol; 2019 Jan; 15(1):73-81. PubMed ID: 30381978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiphospholipid syndrome in patients with retinal venous occlusion.
    Paccalin M; Manic H; Bouche G; Landron C; Mercié M; Boinot C; Gombert JM; Roblot P; Dighiero P
    Thromb Res; 2006; 117(4):365-9. PubMed ID: 16461072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study).
    Bazzan M; Vaccarino A; Stella S; Sciascia S; Montaruli B; Bertero MT; Carignola R; Roccatello D;
    Lupus; 2016 Apr; 25(5):479-85. PubMed ID: 26657216
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary, secondary, and catastrophic antiphospholipid syndrome: what's in a name?
    Harris EN; Pierangeli SS
    Semin Thromb Hemost; 2008 Apr; 34(3):219-26. PubMed ID: 18720301
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations.
    Avcin T; Cimaz R; Meroni PL
    Lupus; 2002; 11(1):4-10. PubMed ID: 11898917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
    Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
    J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Solid cancer, antiphospholipid antibodies, and venous thromboembolism.
    Font C; Vidal L; Espinosa G; Tàssies D; Monteagudo J; Farrús B; Visa L; Cervera R; Gascon P; Reverter JC
    Autoimmun Rev; 2011 Feb; 10(4):222-7. PubMed ID: 20955822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?
    Sciascia S; Coloma-Bazán E; Radin M; Bertolaccini ML; López-Pedrera C; Espinosa G; Meroni PL; Cervera R; Cuadrado MJ
    Autoimmun Rev; 2017 Nov; 16(11):1109-1114. PubMed ID: 28899804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thrombophilia and cancer.
    Horowitz N; Brenner B
    Pathophysiol Haemost Thromb; 2008; 36(3-4):131-6. PubMed ID: 19176986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
    Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiphospholipid antibodies and malignancy.
    Pham C; Shen YM
    Hematol Oncol Clin North Am; 2008 Feb; 22(1):121-30, vii. PubMed ID: 18207070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tissue factor in the antiphospholipid syndrome.
    Kinev AV; Roubey RA
    Lupus; 2008 Oct; 17(10):952-8. PubMed ID: 18827061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The antiphospholipid syndrome and infections in a child with trisomy 21.
    Hoxha A; Calligaro A; Bortolati M; Tonello M; Guariso G; Ruffatti A
    Autoimmun Rev; 2008 Dec; 8(2):121-3. PubMed ID: 18573354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathogenesis and management of antiphospholipid syndrome.
    Greaves M
    Thromb Res; 2009; 123 Suppl 2():S4-9. PubMed ID: 19217474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.